Table 3.
Sensitivity of the duration (time to achieve pOTTIS) and relative total cost of annual ivermectin (aCDTI), biannual ivermectin (bCDTI) and annual moxidectin (aCDTM) treatment programmes to the percentage of therapeutic coverage and systematic non-compliance
| Baseline endemicity level (microfilarial prevalence) | Systematic non-compliance | 80% overall therapeutic coverage | 60% overall therapeutic coverage | ||||
|---|---|---|---|---|---|---|---|
| Projected duration, in years, of treatment programme (relative cost, in percent) | Projected duration, in years, of treatment programme (relative cost, in percent) | ||||||
| aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | aCDTI | bCDTI (ǂ) | aCDTM (ǂ,†) | ||
| Mesoendemic (40%) | 0.1% | 17 | 11 (113%) | 11 (71%, 63%) | 23 | 14 (108%) | 15 (75%, 70%) |
| 2.0% | 18 | 13 (124%) | 13 (78%, 63%) | 24 | 15 (133%) | 16 (75%, 66%) | |
| 5.0% | 20 | 16 (136%) | 16 (85%, 63%) | 26 | 18 (124%) | 19 (80%, 65%) | |
| Hyperendemic (60%) | 0.1% | 25 | 16 (116%) | 17 (76%, 66%) | 37 | 19 (104%) | 21 (70%, 67%) |
| 2.0% | 28 | 19 (123%) | 20 (80%, 65%) | 42 | 22 (108%) | 24 (72%, 66%) | |
| 5.0% | 32 | 24 (133%) | 24 (83%, 63%) | 49 | 28 (119%) | 29 (76%, 64%) | |
| Highly hyperendemic (80%) | 0.1% | NA | 26 (112%) | 26 (70%, 63%) | NA | 38 (140%) | 46 (96%, 69%) |
| 2.0% | NA | 40 (144%) | 43 (80%, 65%) | NA | NA (160%) | NA (100%, 63%) | |
| 5.0% | NA | NA (160%) | NA (100%, 63%) | NA | NA (160%) | NA (100%, 63%) | |
ǂPercentage cost relative to aCDTI. †Percentage cost relative to bCDTI. NA: Operational thresholds for treatment interruption not attained within the 50-year time horizon (and percentage of costs calculated based on costs of 50 years of treatment). Modelling assumptions are as in the legend of Table 2.